BR112012009828B8 - Método para a produção de uma imunoglobulina glicosilada e seu uso - Google Patents

Método para a produção de uma imunoglobulina glicosilada e seu uso

Info

Publication number
BR112012009828B8
BR112012009828B8 BR112012009828A BR112012009828A BR112012009828B8 BR 112012009828 B8 BR112012009828 B8 BR 112012009828B8 BR 112012009828 A BR112012009828 A BR 112012009828A BR 112012009828 A BR112012009828 A BR 112012009828A BR 112012009828 B8 BR112012009828 B8 BR 112012009828B8
Authority
BR
Brazil
Prior art keywords
immunoglobulin
glycosyled
production
culture medium
immunoglobin
Prior art date
Application number
BR112012009828A
Other languages
English (en)
Other versions
BR112012009828A8 (pt
BR112012009828A2 (pt
BR112012009828B1 (pt
Inventor
Franze Reinhard
Hirashima Chikashi
Link Thomas
Takagi Yoshinori
Takuma Shinya
Tsuda Yuriko
Original Assignee
Hoffmann La Roche
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012009828(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Chugai Pharmaceutical Co Ltd filed Critical Hoffmann La Roche
Publication of BR112012009828A2 publication Critical patent/BR112012009828A2/pt
Publication of BR112012009828A8 publication Critical patent/BR112012009828A8/pt
Publication of BR112012009828B1 publication Critical patent/BR112012009828B1/pt
Publication of BR112012009828B8 publication Critical patent/BR112012009828B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

MÉTODO PARA A PRODUÇÃO DE UMA IMUNOGLOBINA GLICOSILADA É relatado aqui um método para a produção de uma imunoglobina compreendendo as seguintes etapas: a) fornecer uma célula eucariótica compreendendo um ácido nucleico codificado uma imunoglobina , b) cultivar a célula eucariótica em um meio de cultivo em que a quantidade de glicose disponível no meio de cultivo por unidade de tempo é mantida constante e limitada a menos que 80% da quantidade que poderia maximamente ser utilizada pelas células no meio de cultivo por unidade de tempo, e c) recuperar a imunoglobina a partir da cultura.
BR112012009828A 2009-10-26 2010-10-25 Método para a produção de uma imunoglobulina glicosilada e seu uso BR112012009828B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09013455.2 2009-10-26
EP09013455 2009-10-26
PCT/EP2010/066073 WO2011051231A1 (en) 2009-10-26 2010-10-25 Method for the production of a glycosylated immunoglobulin

Publications (4)

Publication Number Publication Date
BR112012009828A2 BR112012009828A2 (pt) 2020-08-18
BR112012009828A8 BR112012009828A8 (pt) 2020-09-24
BR112012009828B1 BR112012009828B1 (pt) 2022-05-03
BR112012009828B8 true BR112012009828B8 (pt) 2022-10-25

Family

ID=42060615

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122022001178-0A BR122022001178B1 (pt) 2009-10-26 2010-10-25 Método para a produção de uma imunoglobulina glicosilada e seu uso
BR112012009828A BR112012009828B8 (pt) 2009-10-26 2010-10-25 Método para a produção de uma imunoglobulina glicosilada e seu uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122022001178-0A BR122022001178B1 (pt) 2009-10-26 2010-10-25 Método para a produção de uma imunoglobulina glicosilada e seu uso

Country Status (19)

Country Link
US (8) US20110117087A1 (pt)
EP (2) EP2493922B1 (pt)
JP (6) JP5711751B2 (pt)
KR (8) KR101436219B1 (pt)
CN (2) CN104928336B (pt)
AU (1) AU2010311567B2 (pt)
BR (2) BR122022001178B1 (pt)
CA (1) CA2773522C (pt)
DK (1) DK2493922T3 (pt)
ES (1) ES2622366T3 (pt)
HK (2) HK1171237A1 (pt)
HU (1) HUE033758T2 (pt)
IL (2) IL218997A0 (pt)
MX (2) MX2012004682A (pt)
PL (1) PL2493922T3 (pt)
SG (2) SG10201913329XA (pt)
SI (1) SI2493922T1 (pt)
TW (6) TWI724448B (pt)
WO (1) WO2011051231A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN1638798A (zh) * 2002-02-14 2005-07-13 中外制药株式会社 包含抗体的溶液制剂
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JPWO2005090405A1 (ja) 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR101436219B1 (ko) * 2009-10-26 2014-09-01 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
BR112013011305A2 (pt) 2010-11-08 2017-07-25 Chugai Pharmaceutical Co Ltd método de tratamento de uma disfunção mediada por il-6, método de tratamento de artrite reumatóide, artigo de fabricação, método de inibição da progressão de dano estrutural articular, composição farmacêutica, método de tratamento de artrite idiopática juvenil (jia) e método de tratamento de arterite de células gigantes (gca)
US20150299313A1 (en) * 2011-10-05 2015-10-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
EP2970916B1 (en) 2013-03-13 2021-04-14 Merck Sharp & Dohme Corp. Adapted lepidopteran insect cells for the production of recombinant proteins
KR102248581B1 (ko) 2013-07-04 2021-05-06 에프. 호프만-라 로슈 아게 혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석
WO2015188009A1 (en) * 2014-06-04 2015-12-10 Amgen Inc. Methods for harvesting mammalian cell cultures
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW201723174A (zh) * 2015-09-03 2017-07-01 持田製藥股份有限公司 重組蛋白質的製造方法
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
AU2018234844B2 (en) 2017-03-17 2024-01-25 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926723A (en) 1974-08-08 1975-12-16 Massachusetts Inst Technology Method of controllably releasing glucose to a cell culture medium
US4657863A (en) * 1982-07-02 1987-04-14 Celanese Corporation Stabilization of a mutant microorganism population
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
JPS62258252A (ja) 1986-04-30 1987-11-10 Koyo Seiko Co Ltd ベルト用オ−トテンシヨナ
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
CA1312030C (en) 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US6238891B1 (en) 1987-11-18 2001-05-29 Cetus Oncology Corporation Method of increasing product expression through solute stress
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
KR0132666B1 (en) 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
JP2998976B2 (ja) 1989-07-20 2000-01-17 忠三 岸本 ヒトインタ―ロイキン―６レセプターに対する抗体
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
DK0527760T3 (da) 1990-04-03 1995-11-27 Genentech Inc Fremgangsmåder og præparater til vaccination mod HIV
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE4037325A1 (de) 1990-11-23 1992-05-27 Karl Mueller U Co Kg Verfahren zur erzeugung von zellmasse und/oder fermentierungsprodukten unter sterilen bedingungen sowie vorrichtung zur durchfuehrung des verfahrens
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
JPH05227970A (ja) 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−６受容体に対する再構成ヒト抗体
ES2179821T3 (es) 1991-06-24 2003-02-01 Hcell Technology Inc Celulas pancreaticas secretoras de hormonas y mantenimiento en cultivo a largo plazo.
US5821121A (en) 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
US5610297A (en) 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
EP0567738A3 (en) 1992-05-01 1995-09-06 American Cyanamid Co Controlling perfusion rates in continuous bioreactor culture of animal cells
WO1993022448A1 (en) 1992-05-01 1993-11-11 Teijin Limited Fed batch culture method for protein secreting cells
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
JPH06292592A (ja) * 1993-02-09 1994-10-21 Snow Brand Milk Prod Co Ltd 糖蛋白質の生産方法
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
USH1532H (en) 1993-11-03 1996-05-07 Genetics Institute, Inc. Adaption of mammalian cell lines to high cell densities
ES2116066T3 (es) 1993-11-23 1998-07-01 Genentech Inc Ensayo de activacion del receptor quinasa.
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
DK0756003T3 (da) 1994-02-18 2000-02-07 Teijin Ltd Fremgangsmåde til dyrkning af dyreceller
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
WO1995031483A1 (en) 1994-05-13 1995-11-23 Eclagen Limited Improvements in or relating to peptide delivery
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
EP1884524A3 (en) 1994-10-21 2008-06-25 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment of diseases caused by IL-6 production
ATE214602T1 (de) 1994-12-29 2002-04-15 Chugai Pharmaceutical Co Ltd Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten
DE69636278T2 (de) 1995-02-13 2007-05-03 Chugai Seiyaku K.K. Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
GB9506249D0 (en) * 1995-03-27 1995-05-17 Karobio Ab Media for insect cell cultures
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP3596108B2 (ja) 1995-08-30 2004-12-02 株式会社デンソー 車両用空調装置
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6692742B1 (en) 1996-06-27 2004-02-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6156570A (en) 1997-03-20 2000-12-05 Regents Of The University Of Minnesota Process for the continuous culture of cells
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
JP3707583B2 (ja) 1997-06-06 2005-10-19 株式会社ブリヂストン 金属線用ガイド
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
HU225539B1 (en) 1998-03-17 2007-02-28 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6537782B1 (en) 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
DK1108435T3 (da) * 1998-08-24 2007-02-05 Chugai Pharmaceutical Co Ltd Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6338964B1 (en) 1999-05-07 2002-01-15 Bayer Corporation Process and medium for mammalian cell culture under low dissolved carbon dioxide concentration
KR100942863B1 (ko) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
JP2001101882A (ja) 1999-09-29 2001-04-13 Sony Corp 不揮発性半導体記憶装置
US6284453B1 (en) 1999-09-29 2001-09-04 Steven Anthony Siano Method for controlling fermentation growth and metabolism
AU5901501A (en) 1999-10-19 2001-10-23 Nicholas R. Abu-Absi Measurement of nutrient uptake in cells and methods based thereon
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
AU2001263769A1 (en) 2000-05-30 2001-12-11 Lactascan Aps Method for producing lactic acid
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
EP1298217A4 (en) 2000-07-05 2004-09-08 Mitsubishi Pharma Corp GLYCOPROTEIN PRODUCTION PROCESS
JP4812228B2 (ja) 2000-08-10 2011-11-09 中外製薬株式会社 抗体含有溶液の凝集物生成または白濁抑制方法
AU2001277781A1 (en) * 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
AU1344102A (en) * 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DK1356073T3 (da) 2000-10-20 2010-04-06 Bioneer As Fermenteringsfremgangsmåde til fremstilling af heterologe genprodukter i mælkesyrebakterier
JP4261907B2 (ja) 2000-10-20 2009-05-13 中外製薬株式会社 低分子化アゴニスト抗体
ES2298273T3 (es) * 2000-10-25 2008-05-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos o terapeuticos contra la psoriasis que contienen un antagonista de il-6 como su ingrediente activo.
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
WO2002036164A1 (fr) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent abaissant le taux sanguin de vegf contenant un antagoniste de il-6 en tant que principe actif
IL155482A0 (en) 2000-11-03 2003-11-23 Genentech Inc Metabolic rate shifts in fermentations expressing recombinant proteins
US7109010B2 (en) 2000-11-22 2006-09-19 Nature Works Llc Methods and materials for the synthesis of organic products
CA2433800C (en) 2001-01-05 2016-09-13 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
MXPA03006343A (es) 2001-01-19 2003-10-06 Basf Ag Microorganismos y procesos para produccion mejorada de pantotenato.
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
AU2002256005A1 (en) 2001-03-27 2002-10-08 Smithkline Beecham Corporation Control of glycoforms in igg
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US7531358B2 (en) 2001-04-17 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Method of quantifying surfactant
KR20020088848A (ko) 2001-05-21 2002-11-29 (주)코아바이오텍 세포배양관 및 이를 이용한 대량 세포배양기
EP1404813A4 (en) 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
WO2003009858A1 (en) 2001-07-23 2003-02-06 Zymogenetics, Inc. Fermentation medium and method
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
ES2427964T3 (es) 2002-01-18 2013-11-05 Pierre Fabre Medicament Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
ES2358991T3 (es) 2002-02-08 2011-05-17 Genencor International, Inc. Procedimientos para producir productos finales a partir de sustratos de carbono.
CN1638798A (zh) 2002-02-14 2005-07-13 中外制药株式会社 包含抗体的溶液制剂
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
JP3958089B2 (ja) 2002-03-26 2007-08-15 有限会社新世紀発酵研究所 嫌気性菌の連続培養法
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
CA2484000A1 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US8142810B2 (en) 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
ATE530639T1 (de) 2002-07-03 2011-11-15 Basf Se Mikroorganismen und verfahren zur verbesserten produktion von panthothenat
US7291489B2 (en) 2002-07-03 2007-11-06 Basf Aktiengesellschaft Microorganisms and processes for enhanced production of pantothenate
CN1470632A (zh) 2002-07-25 2004-01-28 谢良志 一种动物细胞的优化流加悬浮培养方法
US8420789B2 (en) 2002-09-11 2013-04-16 Chugai Seiyaku Kabushiki Kaisha Method for removing DNA contaminants from a protein-containing sample
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US7550262B2 (en) 2002-11-05 2009-06-23 Mount Sinai School Of Medicine Of New York University PTPN11 (SHP-2) mutations and cancer
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
ATE475708T1 (de) 2003-01-22 2010-08-15 Glycart Biotechnology Ag Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
NZ540971A (en) 2003-02-13 2008-04-30 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies
KR101142624B1 (ko) 2003-02-24 2012-06-15 추가이 세이야쿠 가부시키가이샤 인터루킨-6 길항제를 함유하는 척수손상 치료제
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
ATE549359T1 (de) 2003-04-02 2012-03-15 Hoffmann La Roche Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
JP4869064B2 (ja) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
SI1623019T1 (sl) * 2003-05-15 2010-10-29 Wyeth Llc Omejeno glukozno dovajanje za živalsko celično kulturo
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
MXPA06001634A (es) 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
BRPI0415505A (pt) 2003-10-17 2006-12-12 Chugai Pharmaceutical Co Ltd agente terapêutico para mesotelioma
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
US7781393B2 (en) 2004-02-25 2010-08-24 Dana-Farber Cancer Institute, Inc. Methods for inhibiting tumor cell growth
AR048335A1 (es) * 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
JPWO2005090405A1 (ja) 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
WO2005115453A2 (en) 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
BRPI0513200A (pt) 2004-07-16 2008-04-29 Pfizer Prod Inc uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US7432359B2 (en) 2004-09-06 2008-10-07 Kirin Pharma Kabushiki Kaisha Anti-A33 antibody
KR20130101161A (ko) 2005-01-05 2013-09-12 추가이 세이야쿠 가부시키가이샤 세포의 배양 방법 및 그 이용
WO2007043641A1 (ja) * 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
DK1945666T3 (da) 2005-10-21 2013-07-01 Genzyme Corp Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf
AU2006305119B2 (en) 2005-10-21 2012-12-20 Chugai Seiyaku Kabushiki Kaisha Agents for treating cardiopathy
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
CA2629147A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101370521A (zh) 2006-01-27 2009-02-18 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
KR101047207B1 (ko) * 2006-03-09 2011-07-06 에프. 호프만-라 로슈 아게 항-약물 항체 분석
MX2008012146A (es) 2006-03-28 2008-10-03 Biogen Idec Inc Anticuerpos anti-receptor 1 de factor de crecimiento tipo insulina (igf-1r) y uso de los mismos.
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
MX2008014804A (es) * 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
WO2008016134A1 (fr) 2006-08-04 2008-02-07 Norihiro Nishimoto PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde
WO2008036600A2 (en) 2006-09-18 2008-03-27 Genentech, Inc. Methods of protein production
JP4355743B2 (ja) * 2006-12-04 2009-11-04 株式会社神戸製鋼所 Ｃｕ合金配線膜とそのＣｕ合金配線膜を用いたフラットパネルディスプレイ用ＴＦＴ素子、及びそのＣｕ合金配線膜を作製するためのＣｕ合金スパッタリングターゲット
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
CN101646459B (zh) 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
PT3187506T (pt) * 2007-05-21 2019-04-24 Alderbio Holdings Llc Anticorpos contra il-6 e sua utilização
EP2174667B1 (en) 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
AR068564A1 (es) 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti- receptor de il-6 (interleuquina 6)
KR101601986B1 (ko) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
CN101802192A (zh) 2007-10-15 2010-08-11 中外制药株式会社 抗体的制备方法
GB2453939A (en) 2007-10-22 2009-04-29 Ubidyne Inc Clockless analogue band-pass delta-sigma modulator
ES2407603T3 (es) 2007-12-15 2013-06-13 F. Hoffmann-La Roche Ag Ensayo de distinción
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009114641A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
DE102008013899A1 (de) * 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag Verfahren zur Herstellung rekombinanter Proteine bei konstantem Gehalt von pCO2 im Medium
TWI528973B (zh) * 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
WO2011013786A1 (ja) 2009-07-31 2011-02-03 Maeda Shin 癌の転移抑制剤
WO2011019622A1 (en) * 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
KR101436219B1 (ko) 2009-10-26 2014-09-01 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
WO2011128096A1 (en) * 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
US20120009177A1 (en) * 2010-06-07 2012-01-12 Roche Molecular Systems, Inc. Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
JP5947802B2 (ja) 2010-11-05 2016-07-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ミックスモードクロマトグラフィーによる抗体捕捉の最適化方法
BR112013011305A2 (pt) 2010-11-08 2017-07-25 Chugai Pharmaceutical Co Ltd método de tratamento de uma disfunção mediada por il-6, método de tratamento de artrite reumatóide, artigo de fabricação, método de inibição da progressão de dano estrutural articular, composição farmacêutica, método de tratamento de artrite idiopática juvenil (jia) e método de tratamento de arterite de células gigantes (gca)
CA2847302C (en) 2011-09-01 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
EP3800204A1 (en) 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
KR102248581B1 (ko) 2013-07-04 2021-05-06 에프. 호프만-라 로슈 아게 혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados

Also Published As

Publication number Publication date
US10501769B2 (en) 2019-12-10
CN104928336A (zh) 2015-09-23
US20220282298A1 (en) 2022-09-08
US11377678B2 (en) 2022-07-05
TW201540837A (zh) 2015-11-01
US20210246478A1 (en) 2021-08-12
JP2020058371A (ja) 2020-04-16
TW201812013A (zh) 2018-04-01
EP2493922B1 (en) 2017-02-15
KR20190060877A (ko) 2019-06-03
TWI724448B (zh) 2021-04-11
BR122022001178B1 (pt) 2022-10-04
SG10201913329XA (en) 2020-02-27
US20220380827A1 (en) 2022-12-01
KR20170110167A (ko) 2017-10-10
US20200080125A1 (en) 2020-03-12
CN102596995A (zh) 2012-07-18
KR20190031342A (ko) 2019-03-25
TW202330028A (zh) 2023-08-01
EP3202785A1 (en) 2017-08-09
TW201938197A (zh) 2019-10-01
BR112012009828A8 (pt) 2020-09-24
CA2773522C (en) 2023-04-18
JP2015128436A (ja) 2015-07-16
TW201619392A (zh) 2016-06-01
TWI675104B (zh) 2019-10-21
KR20120080640A (ko) 2012-07-17
KR20160084500A (ko) 2016-07-13
TWI670375B (zh) 2019-09-01
KR20180014847A (ko) 2018-02-09
WO2011051231A1 (en) 2011-05-05
TWI534264B (zh) 2016-05-21
SI2493922T1 (sl) 2017-06-30
HK1210224A1 (en) 2016-04-15
BR112012009828A2 (pt) 2020-08-18
EP2493922A1 (en) 2012-09-05
BR112012009828B1 (pt) 2022-05-03
CA2773522A1 (en) 2011-05-05
US11021728B2 (en) 2021-06-01
KR101436219B1 (ko) 2014-09-01
JP2017019799A (ja) 2017-01-26
US20160186228A1 (en) 2016-06-30
KR101985153B1 (ko) 2019-05-31
KR20140091070A (ko) 2014-07-18
HK1171237A1 (en) 2013-03-22
JP5982024B2 (ja) 2016-08-31
JP2022116264A (ja) 2022-08-09
KR20210024685A (ko) 2021-03-05
KR101860175B1 (ko) 2018-05-21
JP2013507979A (ja) 2013-03-07
JP6385988B2 (ja) 2018-09-05
PL2493922T3 (pl) 2017-07-31
KR102319842B1 (ko) 2021-11-01
CN102596995B (zh) 2015-08-12
KR102071834B1 (ko) 2020-01-30
CN104928336B (zh) 2020-05-08
KR101961254B1 (ko) 2019-03-22
IL218997A0 (en) 2012-06-28
KR102223417B1 (ko) 2021-03-05
AU2010311567B2 (en) 2015-03-26
US20110117087A1 (en) 2011-05-19
US20210381020A1 (en) 2021-12-09
JP5711751B2 (ja) 2015-05-07
TWI795722B (zh) 2023-03-11
TW202116354A (zh) 2021-05-01
DK2493922T3 (en) 2017-04-24
SG10201510640QA (en) 2016-01-28
HUE033758T2 (en) 2017-12-28
AU2010311567A1 (en) 2012-04-19
JP2019001796A (ja) 2019-01-10
MX2019000097A (es) 2023-01-05
IL263849A (en) 2019-01-31
TW201125976A (en) 2011-08-01
JP7083802B2 (ja) 2022-06-13
US20200181669A1 (en) 2020-06-11
ES2622366T3 (es) 2017-07-06
US11136610B2 (en) 2021-10-05
MX2012004682A (es) 2012-09-07

Similar Documents

Publication Publication Date Title
BR112012009828B8 (pt) Método para a produção de uma imunoglobulina glicosilada e seu uso
BR112012027282A2 (pt) meio de cultura de células aperfeiçoado
BR112012011711A2 (pt) Variantes de beta-glucosidase 1 (bgl1) com propriedades otimizadas, seu método de produção, composição, ácido nucleico, vetor de expressão, célula hospedeira, bem como método de conversão de biomassa em açúcares
BRPI0914440A8 (pt) Método para produção biogênica de etanol e cianobactéria geneticamente modificada
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
WO2008090770A1 (ja) Ｌ－アミノ酸を生産する微生物及びｌ－アミノ酸の製造法
MX345399B (es) Metodo de cultivo de celulas animales.
EP3722438A3 (en) Method for production of moth pheromones in yeast
BRPI0921966A8 (pt) Célula hospedeira de levedura termotolerante, método de fermentar celulose e cultura
AR061069A1 (es) Cepa bg1 de thermoanaaerobacter mathranii y su uso en procedimientos de fermentacion
BR112022017216A2 (pt) Método para produzir células exterminadoras naturais a partir de células-tronco pluripotentes
WO2012142094A3 (en) Compositions and methods for increased ethanol production from biomass
MY160740A (en) Method of producing lauric acid-containing oil or fat
BR112012010052A2 (pt) processo para produção de biodiesel a partir de uma linhagem de levedura
AR082114A1 (es) Metodo para la preparacion de 1,3-propanodiol a partir de sacarosa
AR083934A1 (es) Capa de pichia kluyveri y sus aplicaciones
IN2014DN10003A (pt)
EA201400192A1 (ru) Клетка, ферментирующая пентозы
WO2011100732A3 (en) System and method for renewable resource production, for example, hydrogen production by microbial electrolysis, fermentation, and/or photosynthesis
WO2012124940A3 (ko) 저온 유동성을 개선한 경제적인 수첨 바이오디젤의 제조 방법
BR112016005456A2 (pt) método para produzir um l-aminoácido por um método de fermentação, e, dna isolado
WO2010013906A3 (ko) 인간 줄기세포에서 고활성 줄기세포를 분리하는 방법 및 상기 방법에 의해 분리된 고활성 줄기 세포
BR112013004396A2 (pt) alimentação alcalina
BRPI1008762B8 (pt) métodos para seleção de células de mamífero expressando uma proteína heteróloga, para produzir um produto de interesse e uso de um meio de cultura seletivo
BR112012014696B8 (pt) novas linhagens de levedura para produção de álcool

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2648 DE 05/10/2021 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/10/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2678 DE 03/05/2022, QUANTO AO ITEM (73) ENDERECO DO TITULAR.